Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | TLR2 | O60603 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26700591 | 0.98 | HPGD (0.50) | HPGDDEGS1EPHX2ALDH1A1CYP3A4 | |
| SCHEMBL26700589 | 0.98 | HPGD (0.50) | HPGDDEGS1EPHX2ALDH1A1CYP3A4 | |
| SCHEMBL26148203 | 0.95 | HPGD (0.56) | HPGDDEGS1EPHX2ALDH1A1CYP3A4 | |
| SCHEMBL25977212 | 0.87 | HPGD (0.47) | HPGDEPHX2ALDH1A1CYP3A4RAB9A | |
| SCHEMBL27251492 | 0.84 | FAAH (0.55) | HPGDDEGS1ALDH1A1CYP3A4RAB9A | |
| SCHEMBL23802451 | 0.82 | HPGD (0.55) | HPGDEPHX2ALDH1A1CYP2D6CYP2C19 | |
| SCHEMBL23729880 | 0.81 | HPGD (0.43) | HPGDEPHX2ALDH1A1CYP3A4RAB9A | |
| SCHEMBL26700966 | 0.80 | ALDH1A1 (0.46) | HPGDDEGS1ALDH1A1CYP3A4RAB9A | |
| SCHEMBL13681687 | 0.79 | DEGS1 (0.49) | DEGS1ALDH1A1CYP3A4RAB9ARECQL | |
| SCHEMBL23735659 | 0.79 | FAAH (0.53) | HPGDDEGS1EPHX2ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-11-02 | — | — | US | disclosed |
| WO-2021155321-A2 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2021-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, BRCA1 | HPGD 3620/4885DEGS1 2824/4885EPHX2 2431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.